Professor and Chairman, Texas Tech University Health Sciences Center, United States
Dr. Sanjay K. Srivastava is an esteemed researcher and professor specializing in pediatric pharmacology, oncology, and biotechnology. Currently serving as the James A. ‘Buddy’ Davidson Endowed Professor of Pediatric Pharmacology & Oncology at Texas Tech University Health Sciences Center, Abilene, Texas, Dr. Srivastava has made significant contributions to cancer research, drug discovery, and therapeutic strategies.
Profile
Google Scholar
Evaluation for “Best Researcher Award”
Strengths for the Award
Outstanding Research Contributions:
Dr. Sanjay K. Srivastava has made significant contributions to cancer research, focusing on cancer chemoprevention, drug resistance, molecular pharmacology, and experimental therapeutics. His research on novel drug targets and repurposing existing drugs for cancer treatment is highly impactful. The discovery of targets like STAT-3, NF-kB, HER2, and others, and the exploration of compounds such as capsaicin and piperlongumine, underline his innovative approach and dedication to advancing cancer treatment.
High Recognition and Awards:
Dr. Srivastava has received numerous prestigious awards, including the Chancellor’s Distinguished Research Award (2024), being named a Fellow of AAAS (2023), and being inducted into the National Academy of Inventors (2018). These honors reflect the high regard in which his peers and the scientific community hold his work.
Leadership and Mentorship:
His roles as Professor and Chairman of the Department of Immunotherapeutics and Biotechnology, Associate Dean, and Director of the Abilene Biotechnology Program demonstrate strong leadership and commitment to advancing the field through education and mentorship. The recognition as Outstanding Mentor of the Year and Graduate Mentor of the Year further emphasizes his influence on the next generation of scientists.
Publication and Presentation Record:
Dr. Srivastava has an extensive publication record with numerous abstracts presented at the American Association for Cancer Research (AACR) meetings. His work on the effects of benzyl isothiocyanate, capsaicin, and other compounds is well-documented and has contributed significantly to understanding cancer biology and potential treatments.
Areas for Improvement
Broader Interdisciplinary Collaboration:
While Dr. Srivastava’s research is impressive, further interdisciplinary collaboration could enhance the application of his findings. Engaging with experts in fields such as computational biology, bioinformatics, and clinical trials could help translate his laboratory findings into clinical practice more effectively.
Public Engagement and Communication:
Increasing efforts in public engagement and communication of research findings could help raise awareness about his work. This includes more outreach to non-specialist audiences through public talks, media, and online platforms. This would not only broaden the impact of his research but also foster greater public understanding of cancer research advancements.
Focus on Translational Research:
Expanding efforts in translational research could bridge the gap between laboratory discoveries and clinical applications. Dr. Srivastava’s research could benefit from a more focused approach on how to move promising drug leads and therapeutic strategies from bench to bedside.
Education 🎓
Dr. Srivastava earned his Ph.D. in Biochemical Toxicology from ITRC/Kanpur University, India, in December 1991. He completed his M.S. in Biochemistry and B.S. in Physics, Chemistry, and Mathematics from Lucknow University, India, in 1987 and 1985, respectively. He also holds a Certificate in Business Essentials for Bio-scientists (Mini-MBA) from the Katz Graduate School of Business, University of Pittsburgh, USA, obtained in 2002.
Experience 💼
Dr. Srivastava’s career spans several prestigious roles. He has been the James A. ‘Buddy’ Davidson Endowed Professor of Pediatric Pharmacology & Oncology since 2019. Additionally, he has served as the Chairman of the Department of Immunotherapeutics and Biotechnology and as the Director of the Abilene Biotechnology Program at Texas Tech University Health Sciences Center. His previous roles include Associate Dean for Graduate Program in Pharmaceutical Sciences and Biotechnology, University Distinguished Professor, and Professor in various capacities at Texas Tech University Health Sciences Center and the University of Pittsburgh School of Medicine.
Research Interests 🔬
Dr. Srivastava’s research focuses on cancer chemoprevention, drug resistance, molecular pharmacology, and drug repurposing. He investigates novel drug targets and signaling pathways, including STAT-3, NF-kB, and HER2, with applications in pancreatic, ovarian, breast, melanoma, and brain cancers. His work also explores environmental carcinogen-induced cell signaling pathways and the repurposing of existing drugs for cancer treatment.
Awards 🏆
Dr. Srivastava’s excellence in research and mentorship has been recognized with numerous accolades:
Chancellor’s Distinguished Research Award, Texas Tech University System, 2024.
Fellow of American Association for the Advancement of Sciences (AAAS), 2023.
Member of Sigma Xi, The Scientific Research Honor Society, 2023.
President’s Innovative Startup Award, 2022.
Named in the World’s Top 2% Scientists for 2020-2023, Stanford University.
Graduate Teaching Team of the Year Award, Texas Tech University Health Sciences Center, 2021.
Outstanding Mentor of the Year, IBGSA, Texas Tech University Health Sciences Center, 2020.
James A. ‘Buddy’ Davidson Endowed Professor in Pediatric Pharmacology and Oncology, 2019.
Inducted in the National Academy of Inventors, 2018.
Outstanding Achievement in Cancer Research Award, Society of American Asian Scientists in Cancer Research, 2017.
Publications Top Notes 📚
Dr. Srivastava has authored numerous significant research papers. Notable publications include:
Zhang, R., Loganathan, S., Richards, J., & Srivastava, S. K. (2006). “Role of Cdc25C phosphatase in benzyl isothiocyanate-mediated G2/M arrest in pancreatic cancer cells.” Proc. Am. Assoc. Can. Res., Vol 47, Abstract # 5586.
Zhang, R., & Srivastava, S. K. (2006). “NAC protects against benzyl isothiocyanate induced G2/M arrest and apoptosis in human pancreatic cancer cells.” Proc. Am. Assoc. Can. Res., Vol 47, Abstract # 5587.
Shi, Y., Richards, J., Humphreys, I., Zhang, R., & Srivastava, S. K. (2007). “Benzyl isothiocyanate chemosensitizes BxPC-3 human pancreatic cancer cells to gemcitabine induced growth inhibition and apoptotic death.” Proc. Am. Assoc. Can. Res., Vol 48, Abstract # 5594.
Conclusion
Dr. Sanjay K. Srivastava is a highly deserving candidate for the “Best Researcher Award.” His exceptional contributions to cancer research, coupled with his leadership, mentorship, and recognition within the scientific community, underscore his impact and influence. Addressing areas such as interdisciplinary collaboration, public engagement, and translational research could further enhance his already impressive career and contributions. His work stands as a testament to innovative research and a commitment to advancing cancer treatment and understanding.